Phase II single arm study of durvalumab and olaparib (D plus O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)

被引：0
|
作者：
Fujii, T. [1 ]
Lipkowitz, S. [1 ]
Zimmer, A. D. S. [1 ]
Villanueva, E. [1 ]
Solarz, B. B. [1 ]
Lee, J-M. [1 ]
机构：
[1] Natl Canc Insitute, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435P
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [31] Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC)
    Traina, Tiffany A.
    O'Shaughnessy, Joyce
    Nanda, Rita
    Schwartzberg, Lee
    Abramson, Vandana
    Cortes, Javier
    Peterson, Amy
    Tudor, Iulia Cristina
    Blaney, Martha
    Steinberg, Joyce L.
    Kelly, Catherine
    Trudeau, Maureen
    Awada, Ahmad
    Winer, Eric
    Hudis, Clifford
    Schmid, Peter
    Yardley, Denise A.
    CANCER RESEARCH, 2015, 75
  • [32] Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
    Litton, Jennifer K.
    Beck, J. Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Blum, Joanne L.
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael
    Yuan, Yuan
    Abbattista, Antonello
    Noonan, Kay
    Niyazov, Alexander
    Chakrabarti, Jayeta
    Czibere, Akos
    Symmans, William F.
    Telli, Melinda L.
    ONCOLOGIST, 2023, 28 (10): : 845 - 855
  • [33] The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
    Dent, Rebecca
    Tan, Tira
    Kim, Sung-Bae
    Traina, Tiffany
    McArthur, Heather
    Im, Young-Hyuck
    Creel, Trish
    Blackwell, Kimberly
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
    Shimomura, Akihiko
    Yonemori, Kan
    Yoshida, Masayuki
    Yoshida, Teruhiko
    Yasojima, Hiroyuki
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Naito, Yoichi
    Shimizu, Satoru
    Nakamura, Rikiya
    Hamada, Akinobu
    Michimae, Hirofumi
    Hashimoto, Jun
    Yamamoto, Harukaze
    Kawachi, Asuka
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    TRANSLATIONAL ONCOLOGY, 2019, 12 (10): : 1386 - 1394
  • [35] A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus (an mTOR inhibitor) in patients with stage II/III triple-negative breast cancer (TNBC)
    Mayer, I. A.
    Jovanovic, B.
    Abramson, V. G.
    Mayer, E. L.
    Sanders, M. E.
    Bardia, A.
    Dillon, P. M.
    Kuba, M. G.
    Carpenter, J. T.
    Chang, J. C.
    Lehmann, B. D.
    Meszoely, I. M.
    Grau, A.
    Shyr, Y.
    Arteaga, C. L.
    Chen, X.
    Pietenpol, J. A.
    CANCER RESEARCH, 2013, 73
  • [36] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Wang, Chengzheng
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Lu, Zhenduo
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Yue, Xiayu
    Xia, Qingxin
    Zhang, He
    Yan, Min
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [37] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Chengzheng Wang
    Zhenzhen Liu
    Xiuchun Chen
    Jianghua Qiao
    Zhenduo Lu
    Lianfang Li
    Xianfu Sun
    Chongjian Zhang
    Xiayu Yue
    Qingxin Xia
    He Zhang
    Min Yan
    Nature Communications, 14 (1)
  • [38] MULTICENTER PHASE II STUDY OF APATINIB, A NOVEL INHIBITOR OF VEGFR, IN HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER
    Hu, Xi-chun
    Zhang, Jian
    Xu, Bing-he
    Jiang, Ze-fei
    Tong, Zhong-sheng
    Zhang, Qing-yuan
    Wang, Xiao-jia
    Feng, Ji-feng
    Pang, Dan-mei
    Fan, Min-hao
    Li, Jin
    Wang, Bi-yun
    Wang, Zhong-hua
    Zhang, Qun-ling
    Sun, Si
    Liao, Chun-mei
    Jiang, Hao-yuan
    Shao, Zhi-min
    BREAST, 2013, 22 : S33 - S33
  • [39] Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
    Loibl, Sibylle
    Schneeweiss, Andreas
    Huober, Jens Bodo
    Braun, Michael
    Rey, Julia
    Blohmer, Jens U.
    Furlanetto, Jenny
    Zahm, Dirk Michael
    Hanusch, Claus
    Thomalla, Joerg
    Jackisch, Christian
    Staib, Peter
    Link, Theresa
    Rhiem, Kerstin
    Solbach, Christine
    Fasching, Peter A.
    Burchardi, Nicole
    Denkert, Carsten
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).
    Anders, Carey K.
    Deal, Allison Mary
    Abramson, Vandana Gupta
    Liu, Minetta C.
    Storniolo, Anna Maria
    Carpenter, John T.
    Puhalla, Shannon
    Nanda, Rita
    Melhem-Bertrandt, Amal
    Lin, Nancy U.
    Marcom, Paul K.
    Van Poznak, Catherine H.
    Stearns, Vered
    Melisko, Michelle E.
    Smith, J. Keith
    Karginova, Olga
    Winer, Eric P.
    Perou, Charles M.
    Wolff, Antonio C.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345